NASDAQ · Health care

Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics, Inc. brought in $464M of revenue over the twelve months to June 30, 2026, up 76.1% from a year earlier. Net income was $28.5M, a net margin of 6.1%. In fiscal 2025 capital spending exceeded operating cash flow by $6.3M. At June 30, 2026 it held $34.1M in cash against $108.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Price

$26.92

+2.47% on the day · September 25, 2026

52-week range $17.67 to $31.77

Market cap

$3.4B

Revenue (last 12 months)

$464M

+76.1% year on year

Net margin

6.1%

What Arcutis Biotherapeutics, Inc. does

Arcutis Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARQT.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$376.1M	-$12.2M	-$16.1M	-$0.13	-$6.3M
2024	$196.5M	-$128.4M	-$140M	-$1.16	-$112.3M
2023	$59.6M	-$241.1M	-$262.1M	-$3.78	-$247.5M
2022	$3.7M	-$301.6M	-$311.5M	-$5.66	-$258M
2021	$0	-$206.5M	-$206.4M	-$4.18	-$175.6M
2020	$0	-$136.6M	-$135.7M	-$3.80	-$113.4M

Next report expected around October 27, 2026.

Estimated from its filing rhythm: 52 weeks after its report of October 28, 2025. Not a date the company has announced. See the report calendar

Where ARQT ranks in Health care

Revenue$376.1M

#210 of 523 in Health care · Top 40%

Revenue growth+91.3%

#50 of 437 in Health care · Top 11%

Net margin-4.3%

#212 of 447 in Health care · Top 47%

Free cash flow margin-1.7%

#220 of 408 in Health care · Bottom 46%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Arcutis Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Passive stake (5% or more) SCHEDULE 13G
August 7, 2026
Passive stake (5% or more) SCHEDULE 13G
August 5, 2026
Quarterly report 10-Q · period to June 30, 2026
August 5, 2026
Quarterly results 8-K
July 16, 2026
Executive or director change 8-K
June 9, 2026
Shareholder vote results 8-K
May 12, 2026
Passive stake (5% or more) SCHEDULE 13G
May 8, 2026
Passive stake changed SCHEDULE 13G/A
May 6, 2026
Passive stake changed SCHEDULE 13G/A
May 6, 2026
Quarterly report 10-Q · period to March 31, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 18, 2026. Insider transactions on SEC

Insider trades

What the people running Arcutis Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $1.4M worth of shares in the last 90 days and bought none on the open market. 32% of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$1.4M

last 90 days

Net sold

57,665

$1.4M

Date	Insider	What	Shares	Price	Value	Filing
September 16, 2026	Matsuda MasaruSee Remarks	Soldpre-planned (10b5-1)	3,674	$25.00	$91.9K	Form 4
September 15, 2026	Welgus Howard G.Director	Exercised options	822	$6.52	$5.4K	Form 4
September 15, 2026	Welgus Howard G.Director	Exercised options	1,019	$7.51	$7.7K	Form 4
September 15, 2026	Welgus Howard G.Director	Exercised options	2,255	$8.63	$19.5K	Form 4
September 15, 2026	Welgus Howard G.Director	Soldpre-planned (10b5-1)	4,730	$24.18	$114.4K	Form 4
September 8, 2026	Matsuda MasaruSee Remarks	Soldpre-planned (10b5-1)	9,989	$25.03	$250K	Form 4
August 27, 2026	Curran TerrieDirector	Exercised options	11,148	$7.51	$83.7K	Form 4
August 27, 2026	Curran TerrieDirector	Sold	11,148	$25.03	$279K	Form 4
August 27, 2026	Curran TerrieDirector	Exercised options	27,052	$8.63	$233.5K	Form 4
August 27, 2026	Curran TerrieDirector	Sold	27,052	$25.03	$677.1K	Form 4
August 20, 2026	Curran TerrieDirector	Exercised options	1,072	$7.51	$8.1K	Form 4
August 20, 2026	Curran TerrieDirector	Sold	1,072	$26.04	$27.9K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about ARQT

What does Arcutis Biotherapeutics, Inc. do?

Arcutis Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARQT.

Is Arcutis Biotherapeutics, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $28.5M on revenue of $464M, a net margin of 6.1%.

How much revenue does Arcutis Biotherapeutics, Inc. make?

Over the twelve months to June 30, 2026 Arcutis Biotherapeutics, Inc. reported revenue of $464M. That is 76.1% more than a year earlier.

When did Arcutis Biotherapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 18, 2026.

Similar companies

Compare ARQT with

Compare ARQT with any company

Follow ARQT

Get an email when Arcutis Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ARQT: get an email when it files

Where the numbers come from

Financial figures are the values Arcutis Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.